Acute need. Huge markets. A wide-open playing field. Those are some of the best reasons to invest in psychedelic drug stocks.
Acute need. Huge markets. A wide-open playing field. Those are some of the best reasons to invest in psychedelic drug stocks.
Field Trip's new strategic partnership will facilitate bringing its ketamine-assisted psychotherapy for PTSD to military veterans.
Primo Nutraceuticals is commencing preliminary psychedelics research in a partnership with Mecan Biotech.
Numinus rolls out the list of Advisors on its psychedelics Advisory Council
Both Numinus and Mydecine have been rising recently on big volume. Which is the better bet?
The newest psychedelics company plans to focus on both ketamine- and psilocybin-assisted psychedelics R&D.
Mind Cure adds an expert in neuroscience and nutrition to its Advisory Board.
Industry heavyweight Compass Pathways launched the current rally in psychedelic stocks. But four other stocks have been outperforming CMPS.
MindMed has capitalized on its recent market success to raise new capital on more favorable terms.
MindMed announces a CAD$25 million bought-deal financing at CAD$1.05 per unit.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now